"Biotron expects to file an IND application with the USA FDA in 2H2015. This will enable further pivotal trials of the drug to be conducted in the United States and will be a key milestone towards commercialisation."
It's great the company has decided to buy time till August before it showcases the product in US. Good strategy.
"96% of subjects in the BIT225 arm having more than 2 log reduction in virus levels"
Success rate of 96% today sounds highly acceptable even if a third of these fail treatment in August.
Ann: Independent review supports development of BIT225, page-10
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
